Payment overview · 2025
General Payments
$1,261.07
63 reported records · 16 companies
Healthcare provider profile · identity verified
Nicholas Treece, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · ADAMSVILLE, TN · NPI 1679923759
Verified facts
What the public records show
CMS Open Payments records show Nicholas Treece, D.O. received $1,261.07 in general payments during 2025 across 63 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 630 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $331.62 | 26.3% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $205.10 | 16.3% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $127.92 | 10.1% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $103.16 | 8.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $101.14 | 8.0% | 6 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $73.25 | 5.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.08 | 5.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.56 | 5.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.99 | 3.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.15 | 2.1% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.94 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.36 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.29 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.39 | 1.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.23 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.89 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,261.07 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $212.58 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $127.92 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $127.92 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $122.76 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.04 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $106.74 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $103.16 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $101.14 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $101.14 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $82.34 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $73.25 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.56 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $67.56 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $45.99 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.35 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.35 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.73 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $26.94 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 130 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
47 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
107 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
630 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1357 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 844 | 125 |
| Furosemide | Furosemide | 831 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 784 | 121 |
| Losartan Potassium | Losartan Potassium | 751 | 97 |
| Potassium Chloride | Potassium Chloride | 721 | 79 |
| Lisinopril | Lisinopril | 702 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 665 | 108 |
| Eliquis | Apixaban | 630 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 590 | 83 |
| Sertraline Hcl | Sertraline Hcl | 554 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 549 | 72 |
| Donepezil Hcl | Donepezil Hcl | 541 | 33 |
| Divalproex Sodium | Divalproex Sodium | 523 | 20 |
| Omeprazole | Omeprazole | 510 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 499 | 61 |
| Famotidine | Famotidine | 458 | 65 |
| Gabapentin | Gabapentin | 429 | 78 |
| Clopidogrel | Clopidogrel Bisulfate | 369 | 63 |
| Buspirone Hcl | Buspirone Hcl | 365 | 40 |
| Meloxicam | Meloxicam | 361 | 63 |
| Trazodone Hcl | Trazodone Hcl | 344 | 40 |
| Simvastatin | Simvastatin | 311 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 305 | 28 |
| Alprazolam | Alprazolam | 297 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 284 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 277 | 63 |
| Memantine Hcl | Memantine Hcl | 270 | 19 |
| Metformin Hcl | Metformin Hcl | 266 | 59 |
| Levetiracetam | Levetiracetam | 248 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 244 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 220 | 45 |
| Allopurinol | Allopurinol | 205 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 196 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 195 | 56 |
| Mirtazapine | Mirtazapine | 188 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 91 |
| Prednisone | Prednisone | 181 | 40 |
| Atenolol | Atenolol | 180 | 19 |
| Carvedilol | Carvedilol | 180 | 40 |
| Spironolactone | Spironolactone | 180 | 26 |
| Celecoxib | Celecoxib | 176 | 26 |
| Finasteride | Finasteride | 176 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 172 | 11 |
| Metformin Hcl Er | Metformin Hcl | 167 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 24 |
| Divalproex Sodium Er | Divalproex Sodium | 166 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 165 | 59 |
| Paroxetine Hcl | Paroxetine Hcl | 163 | 16 |
| Montelukast Sodium | Montelukast Sodium | 148 | 35 |
| Risperidone | Risperidone | 138 | suppressed |
| Januvia | Sitagliptin Phosphate | 134 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 132 | suppressed |
| Jardiance | Empagliflozin | 130 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 130 | 16 |
| Glimepiride | Glimepiride | 127 | 31 |
| Ibuprofen | Ibuprofen | 123 | 17 |
| Methocarbamol | Methocarbamol | 117 | suppressed |
| Ezetimibe | Ezetimibe | 114 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 113 | 20 |
| Aripiprazole | Aripiprazole | 112 | suppressed |
| Gemfibrozil | Gemfibrozil | 109 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 108 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 107 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 13 |
| Lactulose | Lactulose | 100 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 99 | suppressed |
| Olanzapine | Olanzapine | 98 | suppressed |
| Clonazepam | Clonazepam | 95 | 17 |
| Ramelteon | Ramelteon | 93 | suppressed |
| Haloperidol | Haloperidol | 91 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 20 |
| Estradiol | Estradiol | 90 | 12 |
| Nystatin | Nystatin | 90 | 32 |
| Azithromycin | Azithromycin | 89 | 72 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 24 |
| Benazepril Hcl | Benazepril Hcl | 84 | 16 |
| Baclofen | Baclofen | 82 | suppressed |
| Lorazepam | Lorazepam | 82 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 80 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 79 | 25 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 79 | suppressed |
| Topiramate | Topiramate | 79 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 33 |
| Ozempic | Semaglutide | 74 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 17 |
| Verapamil Er | Verapamil Hcl | 72 | suppressed |
| Dutasteride | Dutasteride | 71 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 70 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | suppressed |
| Sucralfate | Sucralfate | 70 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 55 |
| Chlorthalidone | Chlorthalidone | 67 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | suppressed |
| Mounjaro | Tirzepatide | 66 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 20 |
| Digoxin | Digoxin | 64 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 64 | 14 |
| Methylprednisolone | Methylprednisolone | 64 | 59 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 63 | 15 |
| Pregabalin | Pregabalin | 63 | 15 |
| Ondansetron Odt | Ondansetron | 62 | 28 |
| Propranolol Hcl | Propranolol Hcl | 62 | suppressed |
| Xarelto | Rivaroxaban | 61 | 15 |
| Desmopressin Acetate | Desmopressin Acetate | 60 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 17 |
| Acyclovir | Acyclovir | 57 | 15 |
| Glipizide | Glipizide | 56 | 12 |
| Bupropion Xl | Bupropion Hcl | 55 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 55 | 24 |
| Cimetidine | Cimetidine | 54 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 28 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Cephalexin | Cephalexin | 52 | 37 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 12 |
| Fenofibrate | Fenofibrate,micronized | 52 | suppressed |
| Linzess | Linaclotide | 52 | 13 |
| Primidone | Primidone | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 41 |
| Amoxicillin | Amoxicillin | 49 | 46 |
| Fluconazole | Fluconazole | 49 | 27 |
| Promethazine Hcl | Promethazine Hcl | 49 | 21 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 48 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 47 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 23 |
| Venlafaxine Hcl | Venlafaxine Hcl | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | 14 |
| Vilazodone Hcl | Vilazodone Hcl | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 33 |
| Roflumilast | Roflumilast | 42 | suppressed |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Ranolazine Er | Ranolazine | 40 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | suppressed |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Naproxen | Naproxen | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 28 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 31 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 31 | 29 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 31 | suppressed |
| Xifaxan | Rifaximin | 30 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 23 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 28 | suppressed |
| Lubiprostone | Lubiprostone | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Ramipril | Ramipril | 25 | suppressed |
| Mirabegron Er | Mirabegron | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 14 |
| Colchicine | Colchicine | 23 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | 13 |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 21 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 13 |
| Latanoprost | Latanoprost | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 18 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Benzonatate | Benzonatate | 16 | 13 |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | 11 |
| Meropenem | Meropenem | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Menest | Estrogens,esterified | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Permethrin | Permethrin | 12 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,261.07 · 63 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, JARDIANCE, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Symbravo, UBRELVY, VOQUEZNA, VRAYLAR, VYKAT XR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error